Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
ACT-10041239 by Idorsia Pharmaceutical for Demyelinating Diseases: Likelihood of Approval
ACT-10041239 is under clinical development by Idorsia Pharmaceutical and currently in Phase I for Demyelinating Diseases. According to GlobalData, Phase...